Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Elife ; 112022 04 22.
Artigo em Inglês | MEDLINE | ID: mdl-35451955

RESUMO

To identify roles of RNA binding proteins (RBPs) in the differentiation or survival of antibody secreting plasma cells we performed a CRISPR/Cas9 knockout screen of 1213 mouse RBPs for their ability to affect proliferation and/or survival, and the abundance of differentiated CD138 + cells in vitro. We validated the binding partners CSDE1 and STRAP as well as the m6A binding protein YTHDF2 as promoting the accumulation of CD138 + cells in vitro. We validated the EIF3 subunits EIF3K and EIF3L and components of the CCR4-NOT complex as inhibitors of CD138 + cell accumulation in vitro. In chimeric mouse models YTHDF2-deficient plasma cells failed to accumulate.


Assuntos
Plasmócitos , Proteínas de Ligação a RNA , Animais , Proteínas de Transporte , Camundongos , Proteínas de Ligação a RNA/genética , Proteínas de Ligação a RNA/metabolismo
2.
J Exp Med ; 218(3)2021 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-33156926

RESUMO

The mRNA N6-methyladenosine (m6A) modification has emerged as an essential regulator of normal and malignant hematopoiesis. Inactivation of the m6A mRNA reader YTHDF2, which recognizes m6A-modified transcripts to promote m6A-mRNA degradation, results in hematopoietic stem cell (HSC) expansion and compromises acute myeloid leukemia. Here we investigate the long-term impact of YTHDF2 deletion on HSC maintenance and multilineage hematopoiesis. We demonstrate that Ythdf2-deficient HSCs from young mice fail upon serial transplantation, display increased abundance of multiple m6A-modified inflammation-related transcripts, and chronically activate proinflammatory pathways. Consistent with the detrimental consequences of chronic activation of inflammatory pathways in HSCs, hematopoiesis-specific Ythdf2 deficiency results in a progressive myeloid bias, loss of lymphoid potential, HSC expansion, and failure of aged Ythdf2-deficient HSCs to reconstitute multilineage hematopoiesis. Experimentally induced inflammation increases YTHDF2 expression, and YTHDF2 is required to protect HSCs from this insult. Thus, our study positions YTHDF2 as a repressor of inflammatory pathways in HSCs and highlights the significance of m6A in long-term HSC maintenance.


Assuntos
Adenosina/análogos & derivados , Células-Tronco Hematopoéticas/metabolismo , Inflamação/genética , Proteínas de Ligação a RNA/metabolismo , Adenosina/metabolismo , Animais , Linhagem da Célula , Proliferação de Células , Senescência Celular , Deleção de Genes , Hematopoese , Transplante de Células-Tronco Hematopoéticas , Inflamação/patologia , Linfócitos/metabolismo , Camundongos Endogâmicos C57BL , Células Mieloides/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo
3.
Cell Stem Cell ; 25(1): 137-148.e6, 2019 07 03.
Artigo em Inglês | MEDLINE | ID: mdl-31031138

RESUMO

Acute myeloid leukemia (AML) is an aggressive clonal disorder of hematopoietic stem cells (HSCs) and primitive progenitors that blocks their myeloid differentiation, generating self-renewing leukemic stem cells (LSCs). Here, we show that the mRNA m6A reader YTHDF2 is overexpressed in a broad spectrum of human AML and is required for disease initiation as well as propagation in mouse and human AML. YTHDF2 decreases the half-life of diverse m6A transcripts that contribute to the overall integrity of LSC function, including the tumor necrosis factor receptor Tnfrsf2, whose upregulation in Ythdf2-deficient LSCs primes cells for apoptosis. Intriguingly, YTHDF2 is not essential for normal HSC function, with YTHDF2 deficiency actually enhancing HSC activity. Thus, we identify YTHDF2 as a unique therapeutic target whose inhibition selectively targets LSCs while promoting HSC expansion.


Assuntos
Leucemia Mieloide Aguda/terapia , Células-Tronco Neoplásicas/fisiologia , Proteínas de Ligação a RNA/metabolismo , Animais , Autorrenovação Celular , Hematopoese , Células-Tronco Hematopoéticas , Humanos , Leucemia Mieloide Aguda/genética , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , RNA Interferente Pequeno/genética , Proteínas de Ligação a RNA/genética , Células THP-1
4.
Psychiatr Danub ; 24 Suppl 1: S197-201, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22945223

RESUMO

We assess the number of patients who we have on the Database of a Community Mental Health Team in the UK who have Bipolar Disorder and Borderline Personality Disorder. We report how many of these have been seen as having both disorders. Hence we discuss the issue as to whether Borderline Personality disorder is to be placed within the bipolar spectrum. We note the difficulties regarding the use of phenomenology alone to decide this problem, and we note the similarities in genetics, neuroimaging observations and neurobiological mechanisms among the following conditions; Bipolar Disorder, Unipolar Depression, Post-traumatic Stress Disorder, and Borderline Personality Disorder. Ethiologies such as Trauma, Abuse, Childhood adversity and exposure to War appear to influence all these conditions via epigenetic mechanisms. Hence we argue that for a spectrum to be proposed, conditions in the spectrum need to be underpinned by similar or common Neuroimaging and neurobiological mechanisms.On this basis, it may be reasonable to include Borderline Personality Disorder within a broadly described bipolar spectrum. New details of the common Neurobiological mechanisms continue to emerge.


Assuntos
Transtorno Bipolar/diagnóstico , Transtorno Bipolar/epidemiologia , Transtorno da Personalidade Borderline/diagnóstico , Transtorno da Personalidade Borderline/epidemiologia , Transtorno Bipolar/etiologia , Transtorno Bipolar/psicologia , Transtorno da Personalidade Borderline/etiologia , Transtorno da Personalidade Borderline/psicologia , Serviços Comunitários de Saúde Mental , Comorbidade , Estudos Transversais , Bases de Dados Factuais , Inglaterra , Epigênese Genética , Humanos , Acontecimentos que Mudam a Vida , Estudos Retrospectivos , Fatores de Risco
5.
J AOAC Int ; 90(2): 550-67, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17474525

RESUMO

A liquid chromatography/electrospray ionization-tandem mass spectrometry (LC/ESI-MS/MS) method was developed and validated to determine 90 pesticides in apple samples. MS/MS data acquisition was achieved by applying multiple-reaction monitoring of 2 fragment ion transitions to provide a high degree of sensitivity and selectivity for both quantitation and confirmation. Matrix-matched standard calibration curves with the use of isotopically labeled standards (or a chemical analog) as internal standards were used to achieve the best accuracy for the method. Both a conventional method validation procedure and a designed experiment were applied to study the accuracy and precision of the method. A compiled computer program that provided a semiautomated procedure for handling a large number of calculations was used to calculate the overall recovery, intermediate precision, and measurement uncertainty (MU). In general, the overall recoveries from samples spiked at levels of 10, 50, and 80 microg/kg, ranged from 60.8 to 121.1%, intermediate precision was <10%, and MUs were <30%. Poor accuracy and/or repeatability was observed for pyridate and etofenprox. The method limits of detection based on a signal-to-noise ratio of >3 were usually <1 microg/kg (ppb), except those for aldicarb sulfoxide and pyridaphenthion, which were about 5 microg/kg.


Assuntos
Técnicas de Química Analítica/métodos , Cromatografia Líquida/métodos , Contaminação de Alimentos , Resíduos de Praguicidas/química , Praguicidas/química , Espectrometria de Massas por Ionização por Electrospray/métodos , Automação , Calibragem , Frutas , Espectrometria de Massas , Piretrinas/química , Padrões de Referência , Reprodutibilidade dos Testes , Projetos de Pesquisa , Software
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA